TY - JOUR
T1 - Vitiligo in patients with melanoma
T2 - Normal tissue antigens can be targets for cancer immunotherapy
AU - Rosenberg, Steven A.
AU - White, Donald E.
PY - 1996/5/8
Y1 - 1996/5/8
N2 - Patients with metastatic renal cell cancer and metastatic melanoma treated with high-dose interleukin-2-based immunotherapy were prospectively evaluated for the development of vitiligo. All patients seen in the Surgery Branch, NCI Immunotherapy Clinic, who had been followed for at least 1 year were evaluated. Of 104 patients with metastatic renal cancer none developed vitiligo, though vitiligo was seen in 11 of 74 (15%) patients with metastatic melanoma (p2 = 0.0001). No vitiligo was seen in 27 patients who did not respond to immunotherapy, although vitiligo was seen in 11 of 43 (26%) melanoma patients who had an objective response to IL-2-based immunotherapy (p2 = 0.0002). These findings provide further evidence that the presence of a growing melanoma can sensitize patients to melanocyte-differentiation antigens and that the immune response against these antigens is associated with cancer regression in patients undergoing immunotherapy.
AB - Patients with metastatic renal cell cancer and metastatic melanoma treated with high-dose interleukin-2-based immunotherapy were prospectively evaluated for the development of vitiligo. All patients seen in the Surgery Branch, NCI Immunotherapy Clinic, who had been followed for at least 1 year were evaluated. Of 104 patients with metastatic renal cancer none developed vitiligo, though vitiligo was seen in 11 of 74 (15%) patients with metastatic melanoma (p2 = 0.0001). No vitiligo was seen in 27 patients who did not respond to immunotherapy, although vitiligo was seen in 11 of 43 (26%) melanoma patients who had an objective response to IL-2-based immunotherapy (p2 = 0.0002). These findings provide further evidence that the presence of a growing melanoma can sensitize patients to melanocyte-differentiation antigens and that the immune response against these antigens is associated with cancer regression in patients undergoing immunotherapy.
KW - Antigens, melanocyte-differentiation
KW - Immunotherapy
KW - Melanoma
KW - Vitiligo
UR - http://www.scopus.com/inward/record.url?scp=0030008301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030008301&partnerID=8YFLogxK
U2 - 10.1097/00002371-199601000-00009
DO - 10.1097/00002371-199601000-00009
M3 - Article
C2 - 8859727
AN - SCOPUS:0030008301
VL - 19
SP - 81
EP - 84
JO - Journal of Biological Response Modifiers
JF - Journal of Biological Response Modifiers
SN - 1524-9557
IS - 1
ER -